DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI Congress
(Thomson Reuters ONE) -
Press Release
Montrouge, France, June 17, 2017
DBV Technologies Highlights Poster Presentations on EPIT(®) at the 2017 EAACI
Congress
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) today announced that four abstracts were accepted for poster presentation
at the 2017 European Academy of Allergy and Clinical Immunology (EAACI) Annual
Congress in Helsinki, Finland, June 17-21, 2017. These abstracts became
available on the EAACI meeting website at 8:00 AM CEST today.
"We are looking forward to joining the distinguished allergy and immunology
community at this year's EAACI Congress," said Dr. Pierre-Henri Benhamou,
Chairman & Chief Executive Officer of DBV Technologies. "This is an exciting
time for DBV with Phase III results for Viaskin Peanut expected later this year,
and we are pleased to present additional data on the Viaskin platform and its
potential in the treatment of food allergies at the Congress."
Poster presentations at EAACI include an analysis of immunological data to
peanut allergens from the Viaskin Peanut Phase IIb VIPES clinical trial in
peanut-allergic patients. DBV will also present data from a preclinical study
investigating the therapeutic potential of Viaskin Egg, the Company's third
product candidate, for the treatment of egg allergy, as well as preclinical
mechanistic data of epicutaneous immunotherapy (EPIT).
Viaskin Peanut Immunological Data
"Epicutaneous immunotherapy (EPIT) for peanut allergy modifies IgG4 responses to
major peanut allergens" will be presented by Dr. Stef Koppelman.
* Session Number: TPS 53
* Poster Number: 1363
* Session Title: Risk factors and management of food allergy
* Date/Time: Tuesday, June 20 / 12:00 PM to 1:30 PM
Egg Allergy Preclinical Data
* "Epicutaneous immunotherapy (EPIT) prevents anaphylaxis to egg in sensitized
mice" will be presented by Dr. Sophie Wavrin, DBV Technologies.
* Session Number: PDS 2
* Poster Number: 0346
* Session Title: Immunotherapy - From immune response to real life
treatment
* Date/Time: Sunday, June 18 / 10:30 AM to 12:00 PM
EPIT Mechanism of Action Research
* "Crucial role of Langerhans cells in epicutaneous immunotherapy" will be
presented by Dr. Vincent Dioszeghy, DBV Technologies.
* Session Number: PDS 2
* Poster Number: 0344
* Session Title: Immunotherapy - From immune response to real treatment
* Date/Time: Sunday, June 18 / 10:30 AM to 12:00 PM
* "MicroRNA-sequencing in a mouse model of peanut sensitized mice treated by
EPIT identifies early changes in microRNA expression influencing T-cell
plasticity and Th2 cytokine production" will be presented by Dr. Jorg Tost,
CEA- Institut de Génomique, CNG, Evry, France.
* Session Number: PDS 27
* Poster Number: 0443
* Session Title: Translational approaches to food allergy
* Date/Time: Tuesday, June 20 / 1:30 PM to 3:00 PM
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release may contain forward-looking statements and estimates,
including statements regarding the potential of Viaskin. These forward-looking
statements and estimates are not promises or guarantees and involve substantial
risks and uncertainties. At this stage, the products of the Company have not
been authorized for sale in any country. Among the factors that could cause
actual results to differ materially from those described or projected herein
include uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals and the risk that
historical preclinical results may not be predictive of future clinical trial
results. A further list and description of these risks, uncertainties and other
risks can be found in the Company's regulatory filings with the French Autorité
des Marchés Financiers, the Company's Securities and Exchange Commission filings
and reports, including in the Company's Annual Report on Form 20-F for the year
ended December 31, 2016 and future filings and reports by the Company. Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of the date
hereof. Other than as required by applicable law, DBV Technologies undertakes no
obligation to update or revise the information contained in this Press Release.
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/2113934/804221.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 17.06.2017 - 08:30 Uhr
Sprache: Deutsch
News-ID 548424
Anzahl Zeichen: 7354
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 299 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI Congress"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
